Telomir Pharmaceuticals Reports Promising Preclinical Results for Age Reversal Compound

Telomir Pharmaceuticals, Inc. has announced significant preclinical findings for Telomir-1, a compound aimed at reversing biological aging. The study, conducted with Nagi Biosciences SA, utilized advanced in vivo microfluidic technology. Results showed improved lifespan, mobility, and reversal of age-related decline in model organisms.

Telomir-1 targets the biological drivers of aging and was tested using the nematode Caenorhabditis elegans. The results included enhanced mobility and reduced biological aging, marking the compound as a potential longevity treatment. Plans for human trials are underway, and further research will explore potential applications for conditions like progeria.

Telomir is also investigating the compound's effects on chronic diseases and plans a study on elderly dogs to examine improvements in joint health. These initiatives highlight Telomir-1's broad therapeutic promise.